New application of tumor shared neoantigen epitope peptide or coding nucleic acid thereof
By identifying shared neoantigens with high mutation frequency in multiple tumor types and preparing their HLA-A2 restriction CTL epitope peptides, the problems of low coverage of neoantigens population and low accuracy of epitope peptide prediction are solved, and effective stimulation of cells is achieved Toxic T lymphocytes have a high clinical application value, which specifically kills tumor cells.
Patent Information
- Application Number
- CN202410964628.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-16
- Publication Date
- 2024-11-12
AI Technical Summary
The population coverage of neoantigens in existing tumor immunotherapy is low, which limits its clinical application, and the accuracy of epitope peptide prediction is low, which requires activity test verification.
Identify shared neoantigens with high mutation frequency in multiple tumor types and prepare their HLA-A2 restriction CTL epitope peptides for stimulating cytotoxic T lymphocytes and prepare drugs for preventing and/or treating tumors, such as vaccines or Cell preparation.
The shared neoantigen epitope peptide obtained through identification can effectively induce the production of specific cytotoxic T lymphocytes and specifically kill tumor cells expressing shared neoantigens, and have high clinical application value and therapeutic potential.
Smart Images

Figure CN118924886A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of a tumor-shared new antigen epitope peptide or its encoding nucleic acid in the preparation of a drug for preventing and / or treating tumors. Background Art
[0002] Tumor immunotherapy has developed rapidly in recent years and is considered to be the most promising treatment method. Studies have shown that the clinical efficacy of tumor immunotherapy depends largely on the presence of tumor antigen-specific CD8 + T lymphocytes, in which tumor antigens play an important role. The ideal tumor antigen is a tumor-specific antigen that is expressed only in tumor cells but not in normal cells. Neoantigens are a type of tumor-specific antigen produced by tumor-specific mutations. Because they are not expressed in normal cells, they have high immunogenicity and can be activated by CD4 + T lymphocytes and CD8 + T lymphocytes produce a strong immune response and are considered one of the most ideal targets for tumor immunotherapy.
[0003] At present, neo-epitope vaccines based on neoantigens and neo-epitope-specific T lymphocytes have shown unique advantages in the treatment of solid tumors. However, the vast majority of neoantigens identified at present are patient-specific, with low population coverage, which seriously restricts the clinical application of neo-epitope-based tumor immunotherapy. Therefore, shared neoantigens with broad population coverage will be the key to future clinical applications.
[0004] With the development of second-generation sequencing technology and bioinformatics technology, mutation information of a large number of tumor patients has been included in online databases such as COSMIC and TIMER, and prediction software combined with different algorithms will facilitate the screening of shared neoantigens and the prediction of mutation-specific epitope peptides. However, the accuracy of epitope peptide prediction is low, and it needs to be verified by activity tests to be effective. In addition, the HLA-A2 subtype accounts for about 50% of the Chinese population. Therefore, the identification of HLA-A2-restricted shared neoepitope peptides will have a wide population coverage and can provide new targets and strategies for tumor immunotherapy based on shared neoantigens. Summary of the invention
[0005] In order to overcome the problem of low population coverage of new antigens, the present invention aims to identify shared new antigens with high mutation frequencies in two or more tumor types, and thereby identify new antigen epitope peptides. These new antigen epitope peptides can effectively stimulate and induce the production of new antigen-specific cytotoxic T lymphocytes, which are used to kill tumor cells that share positive expression of new antigens and have good clinical application value. Therefore, the main technical problem solved by the present invention is to provide a tumor shared new antigen epitope peptide or its encoding nucleic acid for use in the preparation of drugs for the prevention and / or treatment of tumors.
[0006] At the same time, the present invention also provides a medicine for preventing and / or treating tumors.
[0007] In order to solve the above technical problems, the present invention provides the following technical solutions:
[0008] A use of a tumor-shared new antigen epitope peptide or its encoding nucleic acid in the preparation of a drug for preventing and / or treating tumors, wherein the amino acids of the tumor-shared new antigen epitope peptide are shown in any one of SEQ ID NOs: 1-5.
[0009] Specifically, the tumor-shared neoantigen epitope peptides are five HLA-A2 restricted CTL epitope peptides derived from three tumor-shared neoantigens CTNNB1, SMAD4, and SMARCA4, and their amino acid sequences are as follows:
[0010] CTNNB1-S37F:YLDSGIH F GA (SEQ ID NO: 1);
[0011] CTNNB1-S37F:Tyr-Leu-Asp-Ser-Gly-Ile-His- Phe -Gly-Ala.
[0012] CTNNB1-T41A:YLDSGIHSGAT A TA (SEQ ID NO: 2);
[0013] CTNNB1-T41A: Tyr-Leu-Asp-Ser-Gly-Ile-His-Ser-Gly-Ala-Thr- Ala -Thr-Ala.
[0014] CTNNB1-T41A:YLDSGIHSGAT A (SEQ ID NO: 3);
[0015] CTNNB1-T41A: Tyr-Leu-Asp-Ser-Gly-Ile-His-Ser-Gly-Ala-Thr- Ala .
[0016] SMAD4-R361C: YVDPSGGD C FCL (SEQ ID NO: 4);
[0017] SMAD4-R361C: Tyr-Val-Asp-Pro-Ser-Gly-Gly-Asp- Cys -Phe-Cys-Leu.
[0018] SMARCA4-T910M:LL M GTPLQNKLPEL (SEQ ID NO: 5);
[0019] SMARCA4-T910M: Leu-Leu- Met -Gly-Thr-Pro-Leu-Gln-Asn-Lys-Leu-Pro-Glu-Leu.
[0020] Specifically, the nucleic acid encoding the tumor-shared new antigen epitope peptide includes DNA or RNA. Without changing the encoded amino acid sequence, it can be modified according to the preference of the codon.
[0021] As a preferred embodiment of the present invention, the medicine includes vaccines, cell preparations and the like.
[0022] Specifically, the drug is a vaccine or cell preparation that can induce the body to produce tumor-shared neoantigen-specific T cell clones. The vaccine can be a nucleic acid vaccine, which contains a nucleic acid sequence encoding a tumor-shared neoantigen epitope peptide, such as a DNA vaccine or an RNA vaccine; or, the vaccine is a recombinant protein vaccine, a synthetic long peptide vaccine, a mixed peptide pool vaccine, etc., and the recombinant protein vaccine, synthetic long peptide vaccine or mixed peptide pool vaccine all contain the amino acid sequence of the tumor-shared neoantigen epitope peptide. The cell preparation contains antigen-presenting cells (such as dendritic cells), and the antigen-presenting cells contain the amino acid sequence of the tumor-shared neoantigen epitope peptide.
[0023] Alternatively, the drug is a cell preparation that can prevent and / or treat tumors that share positive expression of new antigens. The cell preparation comprises modified cells, for example, T cells, NK cells, NK-T cells, CD4 + T cells, CD8 + T cells, tumor-infiltrating lymphocytes (including tumor-infiltrating T lymphocytes), or T cells modified with T cell receptors or chimeric antigen receptors, NK cells, NK-T cells, CD4+ T cells, CD8 + T cells, tumor infiltrating lymphocytes, etc. The T cell receptor or chimeric antigen receptor can specifically recognize tumor-shared new antigen epitope peptides.
[0024] As a preferred embodiment of the present invention, the tumor-shared new antigen epitope peptide can be prepared by chemical synthesis. The chemical synthesis method includes solid phase synthesis, liquid phase synthesis, solid-liquid phase synthesis, etc. Synthesis strategies such as C-terminal synthesis, N-terminal synthesis, segmented synthesis, etc., and conventional modifications are performed at the C-terminal or N-terminal, including modification groups.
[0025] As a preferred embodiment of the present invention, the tumor is a tumor expressing a shared neoantigen, including a malignant tumor, such as cancer.
[0026] Specifically, the tumors include endometrial cancer, hepatocellular carcinoma, colon adenocarcinoma, rectal adenocarcinoma, pancreatic cancer, lung adenocarcinoma, esophageal cancer, breast cancer, low-grade brain glioma, renal papillary cell carcinoma, nodal parisha myofibroblastoma, neuromuscular aberrant tumor, desmoid tumor, juvenile angiofibroma, enamel-type craniopharyngiocarcinoma, hepatoblastoma, pancreatic ductal carcinoma, biliary tract cancer, cerebral hemangioma, skin Merkel cell carcinoma, skin squamous cell carcinoma, melanoma in situ, skin basal cell carcinoma sarcoma, etc.
[0027] A drug for preventing and / or treating tumors, comprising a tumor-shared neoantigen epitope peptide or its encoding nucleic acid, or a T cell receptor, a chimeric antigen receptor or its encoding nucleic acid that specifically recognizes a tumor-shared neoantigen epitope peptide, wherein the amino acid of the tumor-shared neoantigen epitope peptide is as shown in any one of SEQ ID NOs: 1-5.
[0028] As a preferred embodiment of the present invention, the drug is a vaccine, a cell preparation, etc.
[0029] Specifically, the drug is a vaccine or cell preparation that can induce the production of new antigen-specific T cell clones. As mentioned above, the vaccine includes nucleic acid vaccines (such as DNA vaccines, RNA vaccines), recombinant protein vaccines, synthetic long peptide vaccines, mixed peptide pool vaccines, etc. The cell preparation contains antigen-presenting cells (such as dendritic cells), and the antigen-presenting cells contain tumor-shared new antigen epitope peptides.
[0030] Alternatively, the drug is a cell preparation that can prevent and / or treat tumors that share positive expression of new antigens. As described above, the cell preparation comprises modified T cells, NK cells, NK-T cells, CD4 + T cells, CD8 +T cells, tumor infiltrating lymphocytes, etc. The modified cells are cells transfected with nucleic acids encoding T cell receptors or chimeric antigen receptors, or cells modified with T cell receptors or chimeric antigen receptors, and the T cell receptors or chimeric antigen receptors specifically recognize tumor-shared new antigen epitope peptides.
[0031] As a preferred embodiment of the present invention, when the drug is a vaccine, it may also include an immunomodulator or an adjuvant.
[0032] Specifically, the immunomodulator or adjuvant is selected from poly-ICLC, 1018ISS, Amplivax, MF59, AS03, AS04, AS15, BCG, CP-870, CP-893, CpG7909, CyaA, cyclic dinucleotides (such as STING), dSLIM, GM-CSF, IL-2, IC30, IC31, Montanide ISA TM (such as Montanide ISA51) and the like.
[0033] As a preferred embodiment of the present invention, the drug can be administered by topical administration.
[0034] As a preferred embodiment of the present invention, the dosage form of the drug is a pharmaceutically acceptable dosage form, including but not limited to tablets, granules, capsules, powders, pills, sprays, powders for injection, injections, etc. Based on this, the drug also contains pharmaceutically acceptable excipients, including but not limited to coating materials, solvents, solubilizers, adhesives, stabilizers, antioxidants, pH regulators, flavoring agents, etc. The excipient components can be reasonably selected according to common knowledge of pharmacy.
[0035] As a preferred embodiment of the present invention, the dosage of the drug is a therapeutically acceptable dosage.
[0036] Beneficial effects of the present invention:
[0037] The present invention identifies and obtains 5 HLA-A2 restricted CTL epitope peptides derived from 3 tumor shared neoantigens CTNNB1, SMAD4, and SMARCA4 by analyzing TIMER and COSMIC databases, epitope prediction, and in vitro and in vivo immune activity experiments, and its amino acid sequence is shown in SEQ ID NO: 1-5. The shared neoantigen epitope peptide can effectively stimulate and induce the production of neoantigen-specific cytotoxic T lymphocyte clones, can specifically distinguish wild-type and mutant sequences, and specifically kill tumor cells expressing shared neoantigens. The neoantigen epitope peptide has a high patient coverage rate, and it has good therapeutic potential and application prospects when prepared into drugs (such as vaccines and cell preparations) for preventing and / or treating tumors.
[0038] The drug for preventing and / or treating tumors provided by the present invention comprises a tumor-shared new antigen epitope peptide or its encoding nucleic acid, or comprises a T cell receptor, a chimeric antigen receptor or its encoding nucleic acid that specifically recognizes a tumor-shared new antigen epitope peptide, and the drug can induce the production of a mutant peptide-specific CD8 + T lymphocytes can accurately distinguish between wild type and mutant types and have good clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 The results of intracellular factor staining experiments using tumor cell lines (MCF7-WT / MUT) as target cells were obtained by staining nine mutant epitope peptides from three shared neoantigen sources;
[0040] Figure 2 This is a graph showing the results of an intracellular factor staining experiment using the shared new antigen epitope peptides of the present invention with T2A2 cells loaded with epitope peptides as target cells;
[0041] Figure 3 This is a graph showing the experimental results of the killing effect of specific CTLs induced in vitro by the shared new antigen epitope peptides of the present invention on T2A2 cells loaded with epitope peptides;
[0042] Figure 4 This is a graph showing the experimental results of the killing effect of specific CTLs induced in vitro by the shared new antigen epitope peptides of the present invention on tumor cell lines (MCF7-WT / MUT);
[0043] Figure 5 This is a graph showing the experimental results of the killing effect of specific CTLs induced in vitro by the shared new antigen epitope peptides of the present invention on tumor cell lines (SW620-WT / MUT);
[0044] Figure 6 The shared new antigen epitope peptides SEQ ID NO: 1-5 of the present invention were combined with CpG-ODN 1826 in the form of a peptide pool to immunize HLA-A2.1 / K b Results of intracellular factor staining experiments of specific CTLs obtained from transgenic mice;
[0045] Figure 7 The shared new antigen epitope peptides SEQ ID NO: 1-5 of the present invention were combined with CpG-ODN 1826 in the form of a peptide pool to immunize HLA-A2.1 / K b The figure shows the experimental results of the killing effect of specific CTLs obtained from transgenic mice on tumor cell lines (MCF7-WT / MUT).
[0046] The significance analysis symbols involved in the above figures are as follows: * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001.
[0047] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the above drawings obtained in the experimental examples are briefly introduced. It should be understood that the above drawings only show some experimental examples of the present invention and should not be regarded as any limitation on the scope of protection of the claims. For ordinary technicians in this field, other related drawings can also be obtained based on these drawings without creative work. DETAILED DESCRIPTION
[0048] The technical solution of the present invention will be clearly and completely described below in conjunction with specific embodiments and experimental examples. However, it should be understood by those skilled in the art that the embodiments are only used to illustrate the technical solution of the present invention and should not be regarded as limiting the scope of protection of the present invention. Based on the following embodiments, all other implementation schemes obtained by ordinary technicians in the field without making creative work, such as modification, deformation or simple replacement, should belong to the scope of protection of the present invention.
[0049] Unless otherwise specified, the experimental methods used in the following embodiments and experimental examples are all conventional methods; the raw materials, reagents, instruments, etc. used are all commercially available unless otherwise specified; the terms and abbreviations involved have the conventional meanings in the field, such as PBS is phosphate buffered saline.
[0050] Example 1
[0051] This embodiment provides a drug for preventing and treating tumors (positively expressing shared neoantigens), wherein the drug is a synthetic polypeptide vaccine, comprising a pharmaceutically effective amount of a tumor shared neoantigen epitope peptide prepared by the Fmoc solid phase synthesis method, and an appropriate amount of adjuvants and auxiliary materials; the amino acid sequence of the tumor shared neoantigen epitope peptide is shown in any one of SEQ ID NOs: 1-5.
[0052] Example 2
[0053] This embodiment provides a drug for preventing and treating tumors (positively expressing shared neoantigens), wherein the drug is an mRNA vaccine, comprising a pharmaceutically effective amount of mRNA delivered by lipid nanoparticles (LNP), and an appropriate amount of adjuvants and auxiliary materials; the mRNA is codon-optimized and can encode a tumor-shared neoantigen epitope peptide, and the amino acid sequence of the tumor-shared neoantigen epitope peptide is shown in any one of SEQ ID NOs: 1-5.
[0054] Example 3
[0055] This embodiment provides a drug for preventing and treating tumors (positively expressing shared neoantigens), wherein the drug is a cell preparation comprising a pharmaceutically effective amount of modified T cells, and an appropriate amount of adjuvants and auxiliary materials; the T cells are inserted with T cell receptors that can specifically recognize tumor shared neoantigen epitope peptides, the T cell receptors are obtained by screening, and the amino acid sequence of the tumor shared neoantigen epitope peptide is shown in any one of SEQ ID NOs: 1-5.
[0056] Example 4
[0057] This embodiment provides an application of a tumor-shared neoantigen epitope peptide in the preparation of a drug for preventing and treating tumors, comprising: mixing an effective amount of a tumor-shared neoantigen epitope peptide with an appropriate amount of an adjuvant in a certain order to prepare a drug for preventing and treating tumors that positively express shared neoantigens; the amino acids of the tumor-shared neoantigen epitope peptide are as shown in any one of SEQ ID NOs: 1-5.
[0058] Experimental example
[0059] 1. Analysis of mutation frequency of shared neoantigens
[0060] First, the TumorPortal database was used to screen for new antigens with hotspot mutation sites. Subsequently, the mutation frequencies of these new antigens in different tumor types were analyzed through the TIMER database to determine shared new antigens. Finally, the mutation frequencies and hotspot mutation sites of shared new antigens in different tumor subtypes were analyzed through the COSMIC database, and shared new antigens and hotspot mutation sites were selected. The information of antigenic peptides related to shared new antigens and hotspot mutations used in the following experimental examples is shown in Table 1 below, and the epitope prediction results are shown in Table 2 below.
[0061] Table 1 Antigenic peptide sequences associated with shared neoantigens and hotspot mutations
[0062]
[0063] The mutant epitope peptide was prepared by Fmoc solid phase synthesis, and mass spectrometry analysis confirmed that its molecular weight was consistent with the theoretical value.
[0064] 2. In vitro induction of T lymphocytes specific for shared neoantigens and hotspot mutation-related antigenic peptides
[0065] The in vitro induction method of shared new antigens and hotspot mutation-related antigen peptide-specific T lymphocytes includes:
[0066] (1) Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated by density gradient centrifugation and resuspended in RPMI-1640 medium to adjust the cell density to 1×10 65 ml / well in a 6-well plate, 37°C, 5% CO 2 Culture in a cell culture incubator for 4 h.
[0067] (2) After 4 h of incubation, the unattached cells in the wells were aspirated and centrifuged to obtain 5 × 10 6 Adherent cells were induced to differentiate into dendritic cells (DCs) using RPMI-1640 complete medium containing 1000U / mL rhGM-CSF and 500U / mL rhIL-4, and LPS (100ng / mL) was added on day 5 to induce DCs maturation.
[0068] (3) After 4 hours of loading mature DCs with mutant epitope peptides, mature DCs loaded with mutant epitope peptides were co-cultured with T lymphocytes at a ratio of DCs: T lymphocytes = 1:10, stimulated once a week, and co-stimulated 3 times. During this period, half of the medium was replaced every 2 days, and cytokines IL-2 (final concentration: 100U / mL) and IL-7 (final concentration: 10ng / mL) were supplemented. After three rounds of stimulation, the induced cytotoxic T lymphocytes were collected. T2A2 cells loaded with wild-type or mutant epitope peptides and tumor cell lines expressing wild-type or mutant neoantigens (MCF7-WT / MCF-7-MUT, SW620-WT / SW620-MUT) were used as target cells. The results were detected by intracellular factor staining experiments and LDH lactate dehydrogenase cytotoxicity experiments. Figure 1-4 shown.
[0069] 3. In vivo induction of shared neoantigens and hotspot mutation-related antigen peptide-specific T lymphocytes
[0070] In vivo induction method for shared new antigens and hotspot mutation-related antigen peptide-specific T lymphocytes, including:
[0071] (1) 6-8 week old HLA-A2.1 / Kb transgenic mice were randomly divided into two groups: CpG group (CpG-ODN 1826 + saline for dissolving peptides) and CpG + peptide pool group (containing five mutant epitope peptides CTNNB1-S37F, CTNNB1-T41A (14aa), CTNNB1-T41A (12aa), SMAD4-R361C and SMARCA4-T910M and CpG-ODN 1826). The dosage of CpG-ODN 1826 was 30 μg / mouse, and the dosage of peptide was 100 μg / mouse.
[0072] (2) The mutant epitope peptide and CpG-ODN 1826 were diluted to a final volume of 200 μL, and the immunization was performed by subcutaneous injection at multiple points at the base of the tail. The mice were immunized three times, on day 0, day 7, and day 14, respectively.
[0073] (3) On day 19, the mice were killed, and the spleen and lymph nodes were obtained, ground and digested. The cell suspension was then filtered through a sterilized filter into a sterile centrifuge tube and the cells were collected by centrifugation.
[0074] (4) Discard the supernatant and add 5 mL of red blood cell lysis buffer. After lysis, wash with PBS and collect the cells by centrifugation. After centrifugation, discard the supernatant and resuspend the cells in GT-T551 medium to adjust the cell concentration to 5×10 6 pc / ml, plated in 6-well plates and incubated at 37°C, 5% CO 2 Culture in a cell culture incubator.
[0075] (5) On the first day, mutant epitope peptides (Peptide pool, 2.5 μg / mL) and mIL-2 (50 U / mL) were added. The medium was replaced by half every other day and mIL-2 was added. On the fifth day of induction, the induced peptide-specific T lymphocytes were collected. Tumor cell lines expressing wild-type or mutant neoantigens (MCF7-WT / MCF-7-MUT) were used as target cells, and the results were detected by intracellular factor staining experiments and LDH lactate dehydrogenase cytotoxicity experiments. Figure 5-6 As shown, Figure 5 In the right bar graph, blue: MCF7-WT, red: MCF7-MUT.
[0076] 4. Detection Method
[0077] 1. Intracellular factor staining experiment
[0078] Intracellular factor staining assays, including:
[0079] (1) Target cell preparation: T2 cells were collected by centrifugation, and mutant epitope peptides or wild-type epitope peptides were loaded onto T2 cells at a final concentration of 50 μg / mL. The cells were incubated at 37°C and 5% CO 2 Incubate in a cell culture incubator for 4 hours. For tumor cell lines, trypsinize and resuspend, then wash with serum-free medium. After centrifugation and washing, adjust the cell density to 2×10 5 Pieces / mL.
[0080] (2) Preparation of mutant epitope peptide-specific T lymphocytes: The induced T lymphocytes were collected, washed with serum-free medium, and resuspended to adjust the cell density to 2×10 6 Pieces / mL.
[0081] (3) Peptide-specific T lymphocytes and target cells were plated in a 96-well U-bottom plate at a ratio of 10:1 and incubated at 37°C and 5% CO 2 Incubate in a cell culture incubator for 4 hours. After 4 hours of co-incubation, add blocking agent BFA to each well of cells and continue to culture for 3 hours.
[0082] (4) Collect cells from each well into a 1.5 ml EP tube, centrifuge and wash, add 50 μL of diluted cell surface antibodies (CD3, CD8 and FasL), vortex to mix, and incubate at 4°C in the dark for 30 min. After incubation, wash twice with PBS. Set up a blank control group, a CD3 single positive group, a CD8 single positive group and an isotype control group.
[0083] (5) Add 200 μL of fixative to each tube of cells and vortex to mix, then incubate at room temperature in the dark for 30 min. After the incubation, add 800 μL of diluted permeabilization agent, then centrifuge to collect the cells.
[0084] (6) Add 50 μL of intracellular factor antibody (IFN-γ, except for the blank group, single positive group and isotype control group) diluted with membrane permeabilization agent, vortex mix and incubate at 4°C in the dark for 30 min. After incubation, wash twice with PBS.
[0085] (7) Discard the supernatant, resuspend the cells in 200 μL PBS, and analyze by flow cytometry.
[0086] 2. LDH lactate dehydrogenase cytotoxicity experiment
[0087] LDH lactate dehydrogenase cytotoxicity test method, including:
[0088] (1) Target cell preparation: T2 cells were collected by centrifugation, and mutant epitope peptides or wild-type epitope peptides were loaded onto T2 cells at a final concentration of 50 μg / mL. The cells were incubated at 37°C and 5% CO 2 Incubate in a cell culture incubator for 4 hours. For tumor cell lines, trypsinize and resuspend, then wash with serum-free medium. Centrifuge and wash the target cells, and adjust the cell density to 1×10 5 Pieces / mL.
[0089] (2) Preparation of mutant epitope peptide-specific T lymphocytes: The induced T lymphocytes were collected, washed with serum-free medium, and resuspended to adjust the cell density to 5×10 6 Pieces / mL.
[0090] (3) Peptide-specific T lymphocytes and target cells were plated in 96-well U-bottom plates at an effector-target ratio (E:T) of 12.5:1, 25:1, and 50:1. The number of target cells was 5,000 per well, and the final volume per well was 100 μL. The culture medium was incubated at 37°C and 5% CO 2Incubate in the cell culture incubator for 4 hours.
[0091] Set up the experimental group:
[0092] Target cell spontaneous release group: 50 μL target cells + 50 μL serum-free medium;
[0093] Target cell maximum release group: 50 μL target cells + 50 μL serum-free medium + 10 μL lysis solution;
[0094] Background control group: 100 μL serum-free medium;
[0095] Volume correction group: 100 μL serum-free IMDM + 10 μL lysis buffer;
[0096] Experimental group: 50 μL target cells + 50 μL T lymphocytes corresponding to different effector-target ratios.
[0097] (4) 45 minutes before the end of incubation, add 10 μL of lysis solution to each of the target cell maximum release group and volume correction group. Take 50 μL of supernatant and transfer it to another flat-bottom 96-well plate. Add 50 μL / well of diluted substrate mixture and incubate at room temperature in the dark for 30 minutes. Add 50 μL / well of stop solution, remove bubbles, and detect at 490 nm within 1 hour.
[0098] V. Experimental Results and Analysis
[0099] Table 2 Prediction results of antigenic peptides related to shared neoantigens and hotspot mutations
[0100]
[0101] Table 2 shows the prediction results of tumor shared neoantigen epitope peptides. As can be seen from Table 2, for the CTNNB1 S37F site, SEQ ID NO: 6-8 has comparable predicted affinity to SEQ ID NO: 1. For the CTNNB1 T41A site, SEQ ID NO: 9 has better predicted affinity than SEQ ID NO: 2 and SEQ ID NO: 3.
[0102] Figure 1 The results of the intracellular factor staining experiment of nine mutant epitope peptides from three shared neoantigen sources, the target cells are MCF7-WT and MCF7-MUT. Figure 1It can be seen that the five shared new antigen epitope peptides SEQ ID NO: 1-5 can induce mutant epitope peptide-specific cytotoxic T lymphocytes in three healthy donors. For the CTNNB1 S37F site, although SEQ ID NO: 6-8 and SEQ ID NO: 1 have comparable predicted affinity, the intracellular results show that the CTLs induced by these three mutant epitope peptides cannot distinguish wild-type tumor cells from mutant tumor cells well. For the CTNNB1 T41A site, SEQ ID NO: 9 is only one amino acid different from SEQ ID NO: 2 and SEQ ID NO: 3, and the predicted affinity is also the best among the three mutant epitope peptides, but the intracellular factor staining results show that SEQ ID NO: 9 induced CTLs cannot distinguish wild-type tumor cells from mutant tumor cells well. It can be seen that most of the mutant epitope peptides obtained only by epitope peptide prediction methods cannot distinguish wild-type from mutant types. For the development of vaccines related to mutant epitope peptides, it is of practical significance to verify the effectiveness of activity tests.
[0103] Figure 2 The results of the intracellular factor staining experiment of the shared new antigen epitope peptide of the present invention are shown in FIG. The target cells are T2A2 cells loaded with mutant epitope peptides and wild-type epitope peptides. Figure 2 It can be seen that compared with the T2A2 cell group loaded with wild-type epitope peptides, the five shared new antigen epitope peptides of SEQ ID NO: 1-5 induced healthy donors (HLA-A2 + ) After co-incubation of CTLs obtained from PBMCs with T2A2 cells loaded with mutant epitope peptides, they had higher IFN-γ secretion levels and FasL expression levels, and there was a significant difference between the two groups. The experimental results showed that the five shared new antigen epitope peptides SEQ ID NO: 1-5 had good immunogenicity in vitro.
[0104] Figure 3 The figure is the experimental result of the killing effect of specific CTLs induced in vitro by the shared new antigen epitope peptide of the present invention on T2A2 cells loaded with epitope peptide. Figure 3 It can be seen that the five shared new antigen epitope peptides of SEQ ID NO: 1-5 induce healthy donors (HLA-A2 + ) The CTLs obtained from PBMCs can specifically kill T2A2 cells loaded with mutant epitope peptides and have good immunogenicity.
[0105] Figure 4 , Figure 5The results of the experimental study on the killing effect of specific CTLs induced by the shared new antigen epitope peptides of the present invention on wild-type tumor cells and mutant tumor cells in vitro. As can be seen from the figure, the five shared new antigen epitope peptides of SEQ ID NO: 1-5 induce the killing of healthy donors (HLA-A2 + The killing rate of CTLs obtained from PBMCs against mutant tumor cell lines MCF7-MUT and SW620-MUT was significantly higher than that against wild-type tumor cell lines MCF7-WT and SW620-WT. This result was further found through killing experiments that the CTLs induced in vitro by the five shared new antigen epitope peptides SEQ ID NO: 1-5 can specifically recognize and kill shared new antigen-positive tumor cells.
[0106] Figure 6 The shared new antigen epitope peptides SEQ ID NO: 1-5 of the present invention were combined with CpG-ODN 1826 in the form of a peptide pool to immunize HLA-A2.1 / K b Results of the specific intracellular factor staining experiment of CTLs obtained from transgenic mice. Figure 6 It can be seen that compared with the CpG alone immunization group, the CD8 + T lymphocytes were able to specifically distinguish between MCF7-MUT and MCF7-WT, with significantly higher levels of IFN-γ + CD8 + T cells and FasL + CD8 + T cells.
[0107] Figure 7 The shared new antigen epitope peptides SEQ ID NO: 1-5 of the present invention were combined with CpG-ODN 1826 in the form of a peptide pool to immunize HLA-A2.1 / K b The results of the experiment on the killing effect of specific CTLs obtained from transgenic mice on tumor cell lines (MCF7-WT / MUT). Figure 7 It can be seen that compared with the CpG immunization group alone, the killing efficiency of CTLs induced by CpG+peptide pool against the MCF7-MUT target cell group was significantly higher than that of the MCF7-WT target cell group, and the killing efficiency increased with the increase of the effect-target ratio. The experimental results show that the CTLs induced in vivo by the peptide pool of the present invention can specifically recognize and kill tumor cells that share new antigens.
[0108] It can be seen from the above experimental results that the present invention identified and obtained 5 HLA-A2 restricted CTL epitope peptides (as shown in SEQ ID NO: 1-5) derived from 3 tumor shared neoantigens CTNNB1, SMAD4, and SMARCA4 by analyzing the TIMER and COSMIC databases, epitope prediction and in vitro and in vivo immune activity experiments. The shared neoantigen epitope peptides can effectively stimulate and induce the production of neoantigen-specific cytotoxic T lymphocyte clones, can specifically distinguish between wild-type and mutant sequences, and specifically kill tumor cells expressing shared neoantigens.
[0109] The new antigen epitope peptides identified by the present invention have a high patient coverage rate, and are prepared into drugs for preventing and / or treating tumors (such as vaccines, cell preparations, etc., or the drugs contain T cell receptors, chimeric antigen receptors or nucleic acids encoding them that specifically recognize tumor-shared new antigen epitope peptides), which can induce the production of mutant peptide-specific CD8 + T lymphocytes can accurately distinguish between wild type and mutant types, and have good therapeutic potential and clinical application prospects.
[0110] Although the technical solution of the present invention has been described in detail above with general descriptions, specific implementation methods and experimental examples, it should be noted that the embodiments and experimental examples are only used to illustrate the technical solution and technical effects of the present invention, and should not be regarded as any limitation on the protection scope of the present invention. Simple deformation, modification or improvement based on the technical concept of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. Use of a tumor-shared new antigen epitope peptide or its encoding nucleic acid in the preparation of a drug for preventing and / or treating tumors, Features: The amino acids of the tumor-shared new antigen epitope peptide are shown in any one of SEQ ID NOs: 1, 3-5.
2. The use according to claim 1, Features: The drug is a vaccine or cell preparation that can induce the body to produce tumor-shared neoantigen-specific T cell clones; The vaccine is a nucleic acid vaccine, which contains a nucleic acid sequence encoding a tumor-shared new antigen epitope peptide; or, the vaccine is a recombinant protein vaccine, a synthetic long peptide vaccine or a mixed peptide pool vaccine, which contains an amino acid sequence of a tumor-shared new antigen epitope peptide; The cell preparation comprises antigen-presenting cells, and the antigen-presenting cells comprise the amino acid sequence of a tumor-shared neoantigen epitope peptide.
3. The use according to claim 1, Features: The drug is a cell preparation that can prevent and / or treat tumors that share positive expression of new antigens; The cell preparation comprises modified cells, wherein the modified cells are T cells, NK cells, NK-T cells, CD4 + T cells, CD8 + T cells or tumor infiltrating lymphocytes, or the modified cells are T cells, NK cells, NK-T cells, CD4 + T cells, CD8 + T cells or tumor infiltrating lymphocytes; the T cell receptor or chimeric antigen receptor specifically recognizes tumor-shared neoantigen epitope peptides.
4. The use according to any one of claims 1 to 3, Features: The tumor-shared new antigen epitope peptide is prepared by chemical synthesis, and the synthesis strategies include C-terminal synthesis, N-terminal synthesis, and segmented synthesis; The tumor-shared new antigen epitope peptide prepared by chemical synthesis comprises a modification group at the C-terminus or N-terminus.
5. The use according to any one of claims 1 to 3, Features: The tumors are tumors that share positive expression of new antigens, including endometrial cancer, hepatocellular carcinoma, colon adenocarcinoma, rectal adenocarcinoma, pancreatic cancer, lung adenocarcinoma, esophageal cancer, breast cancer, low-grade brain glioma, renal papillary cell carcinoma, intranodal parisha myofibroblastoma, neuromuscular aberrant tumor, desmoid tumor, juvenile angiofibroma, enamel-type craniopharyngiocarcinoma, hepatoblastoma, pancreatic ductal carcinoma, biliary tract cancer, cerebral hemangioma, skin Merkel cell carcinoma, skin squamous cell carcinoma, melanoma in situ, and skin basal cell carcinoma sarcoma.
6. A drug for preventing and / or treating tumors, Features: The drug comprises a tumor-shared neoantigen epitope peptide or a nucleic acid encoding it, or comprises a T cell receptor, a chimeric antigen receptor or a nucleic acid encoding it that specifically recognizes a tumor-shared neoantigen epitope peptide, and the amino acid of the tumor-shared neoantigen epitope peptide is shown in any one of SEQ ID NOs: 1, 3-5.
7. The drug for preventing and / or treating tumors according to claim 6, Features: The drug is a vaccine or cell preparation that can induce the body to produce tumor-shared neoantigen-specific T cell clones; The vaccine is a nucleic acid vaccine, which contains a nucleic acid sequence encoding a tumor-shared new antigen epitope peptide; or, the vaccine is a recombinant protein vaccine, a synthetic long peptide vaccine or a mixed peptide pool vaccine, which contains an amino acid sequence of a tumor-shared new antigen epitope peptide; The cell preparation comprises antigen-presenting cells, and the antigen-presenting cells comprise the amino acid sequence of a tumor-shared neoantigen epitope peptide.
8. The drug for preventing and / or treating tumors according to claim 6, Features: The drug is a cell preparation that can prevent and / or treat tumors that share positive expression of new antigens; The cell preparation comprises modified cells, wherein the modified cells are T cells, NK cells, NK-T cells, CD4 + T cells, CD8 + T cells or tumor infiltrating lymphocytes, or the modified cells are T cells, NK cells, NK-T cells, CD4 + T cells, CD8 + T cells or tumor infiltrating lymphocytes; the T cell receptor or chimeric antigen receptor specifically recognizes tumor-shared neoantigen epitope peptides.
9. The drug for preventing and / or treating tumors according to claim 7, Features: When the drug is a vaccine, it may also include an immunomodulator or an adjuvant; The immunomodulator or adjuvant is selected from one or more of poly-ICLC, 1018ISS, Amplivax, MF59, AS03, AS04, AS15, CP-870, CP-893, CpG7909, CyaA, cyclic dinucleotide, dSLIM, GM-CSF, IL-2, IC30, IC31, MontanideISA51.
10. The drug for preventing and / or treating tumors according to claim 6, Features: The dosage form of the drug is a pharmacotherapy acceptable dosage form, including tablets, granules, capsules, powders, pills, sprays, powders for injection, and injections; and / or, the drug may be administered topically; And / or, the dosage of the drug is a therapeutically acceptable dosage.
